Related Experiment Video
Updated: Jun 11, 2026

Modeling Healthy and Dysbiotic Vaginal Microenvironments in a Human Vagina-on-a-Chip
Published on: February 16, 2024
Pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis
Xin Wang1, Tatiana N Nanovskaya, Ying Zhan
1Department of Obstetrics and Gynecology, The University of Texas Medical Branch, Galveston, TX 77555-0587, USA.
Objective:
The present study was undertaken to investigate the pharmacokinetics of metronidazole in pregnant patients with bacterial vaginosis.
Methods:
Twenty patients received metronidazole (Flagyl ®, Pfizer, 235 East 42nd Street, NY, NY 10017) oral dose 500 mg twice a day for 3 consecutive days. Pharmacokinetic analyses of metronidazole were performed after a single oral dose on the morning of day 4.
Results:
Although absolute estimates of metronidazole total body exposure were highest in women during early term pregnancy, weight-corrected estimates of exposure maximum plasma drug concentration (C(max)) and the area under the plasma concentration-versus-time curve (AUC(0-12)), along with apparent oral clearance and distribution volume, were not significantly different between women at early, middle, and late stages of pregnancy and were in the range of reported values for nonpregnant patients receiving a similar dose.
Conclusions:
The pharmacokinetic profile of metronidazole did not change at the different time points assessed during pregnancy.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Microbiota Modulation by Antibiotics
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Microbiota of the Urogenital Tract
Trichomoniasis
Pharmacokinetics in Pediatric Patients: Drug Excretion

